Table 7.
Comparison between the patients with HCC and those without HCC in the 94 patients with NVR of past IFN treatment
| Patients with HCC | Patients without HCC | Comparison between patients with HCC and those without HCC | Multiple regression analysis for factors associated with HCC development | ||
|---|---|---|---|---|---|
| (n = 17) | (n = 77) | Odds ratio (95% confidence interval) | p | ||
| Age (yrs) | 69.6±9.3 | 58.9±10.0 | P = 0.0001 | 1.19 (1.08 - 1.32) | p = 0.0007 |
| Gender (male/female) | 9/8 | 47/30 | NS | NS | |
| BMI (kg/m2) | 23.2±3.8 | 22.9±3.3 | NS | ||
| PNPLA3 (GG/CC・CG) | 6/11 | 13/64 | P = 0.0871 | 3.95 (1.00 - 15.61) | p = 0.0497 |
| AST (IU/L) | 56.35±25.5 | 55.3±52.3 | NS | ||
| ALT (IU/L) | 51.1±38.6 | 63.0±80.0 | NS | ||
| γ-GTP (IU/L) | 44.8±20.6 | 63.1±100.8 | NS | ||
| Albumin (g/dL) | 3.5±1.0 | 4.3±0.4 | p < 0.0001 | ||
| Total bilirubin (mg/dL) | 0.9±0.5 | 0.9±1.1 | NS | ||
| Platelet count (x104/μL) | 10.1±4.1 | 14.9±5.4 | P = 0.0008 | ||
| Prothrombin time (%) | 88.0±14.2 | 98.4±17.3 | P = 0.0295 | ||
| Hyaluronic acid (ng/mL) | 402.2±316.9 | 153.1±186.6 | P = 0.0002 | ||
| α-fetoprotein (ng/mL) | 23.2±20.6 | 9.8±12.1 | P = 0.0005 | ||
| PIVKA-II(mAU/mL) | 28.0±19.4 | 20.2±8.9 | P = 0.0134 | ||
| HCV genotype (1/2/3) | 16/1/0 | 63/13/1 | NS | ||
| HCV RNA (log IU/mL) | 6.2±1.2 | 6.2±1.1 | NS | ||
| Velocity of shear wave (m/s) | 2.20±0.70 | 1.60±0.5 | P = 0.0002 | ||
HCC, hepatocellular carcinoma; IFN, interferon; NVR, non-virological response; BMI, body mass index; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II; NS, not significant.